Why Lundbeck’s INFUSE study could broaden how migraine treatment success is measured
Lundbeck’s new Vyepti data highlight migraine-related cognitive symptom gains. Read what the INFUSE study could change for clinicians and the CGRP market.
Pharma & Biotech
Pharma & Biotech
How Merck’s ENFLONSIA could challenge existing infant RSV prevention pathways in Europe
European Union approval gives Merck’s ENFLONSIA a new opening in infant RSV prevention. Read what it means for rollout, reimbursement, and competition.
Pharma & Biotech
Ensem Therapeutics puts pan-KRAS and WRN into focus as AACR 2026 sharpens its precision oncology pitch
Read how Ensem Therapeutics is positioning ETX-929 and ETX-880 in the KRAS and MSI-H oncology races at AACR 2026.
Pharma & Biotech
Can Volastra Therapeutics turn KIF18A inhibition into a pan-cancer precision oncology platform?
Volastra Therapeutics unveils AACR 2026 biomarker and combination data for KIF18A inhibitors. Read what this means for oncology development.
Pharma & Biotech
Why Gilead’s Arcellx acquisition approval could reshape the multiple myeloma CAR-T race
Gilead has cleared regulatory hurdles for Arcellx. Read why the anito-cel takeover could reshape the multiple myeloma CAR-T market.
Pharma & Biotech
Why everyone watching neurology at AAN 2026 may end up talking about Acadia Pharmaceuticals
Acadia Pharmaceuticals heads to AAN 2026 with Daybue, Nuplazid, and ACP-711 data. Read what the updates could mean for its neurology strategy.
Pharma & Biotech
Salubris Biotherapeutics expands JK06 data at AACR 2026 with encouraging responses in difficult solid tumors
Salubris Biotherapeutics’ JK06 showed early AACR 2026 activity in NSCLC and breast cancer. Read what it could mean for the 5T4 ADC race.
Pharma & Biotech
Can OncoNano Medicine’s ON-BOARD platform solve antigen limits in solid tumor drug delivery?
OncoNano Medicine’s AACR 2026 data spotlight ON-BOARD and ONM-421. Read why pH-targeted tumor delivery could reshape oncology development.
Pharma & Biotech
Can Orum Therapeutics crack one of AML’s hardest problems with ORM-1153? AACR 2026 data spark fresh attention
Orum Therapeutics unveiled AACR 2026 data for ORM-1153 in AML. Read why the CD123 degrader strategy could matter for efficacy and tolerability.
Pharma & Biotech
How NEU-002 could reshape Onchilles Pharma’s systemic solid tumor strategy after AACR 2026
Onchilles Pharma’s NEU-002 showed systemic anti-tumor activity at AACR 2026. Read what the preclinical data could mean for solid tumor development.